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ABSTRACT 
Chlamydia trachomatis is the most common bacterial agent of sexually transmitted 
infections worldwide and a common co-infection in AIDS patients. Chlamydial genital tract 
infections are often asymptomatic; therefore many infections go untreated and result in 
complications like chronic inflammation, ectopic pregnancy, and pelvic inflammatory disease. 
Chlamydia share a unique developmental cycle and under stress, can enter a state known as 
persistence, in which the bacteria are noninfectious but still viable. Removal of the stressor 
allows the chlamydiae to re-enter and complete the developmental cycle. Exposure to low-dose 
quinolones can cause the chlamydiae to enter persistence and halt the developmental cycle. 
Notably, 1 in 20 people living with HIV/AIDS also suffers from chlamydial infections. Since the 
anti-HIV drug Elvitegravir (EVG) is a quinolone derivative, we hypothesized that EVG exposure 
would inhibit chlamydial development. To ascertain whether EVG affects chlamydial 
development, HeLa cells were infected with C. trachomatis or C. muridarum and then either 
mock treated or treated with EVG.  The percent infectivity and production of infectious progeny 
were determined by immunofluorescence assay and chlamydial titer assay, respectively. 
Transmission electron microscopy (TEM) was used to examine chlamydial morphology and 
determine whether EVG caused Chlamydia to become persistent. Though percent infectivity and 
chlamydial morphology were similar between treated and untreated Chlamydia-infected cells, 
the production of infectious progeny was significantly decreased in EVG-exposed Chlamydia-
infected cells. These data indicate that EVG is not a persistence-inducer, but does inhibit 
chlamydial development in vitro. In other studies, we tested chlamydial polymorphic membrane 
protein (PMP) expression in chlamydia/HSV co-infected cells by immunofluorescence staining. 
Since penicillin-induced persistence decreases the expression of some chlamydial PMPs, we 
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hypothesized that expression of PMP-A and PMP-B would be decreased by HSV-induced 
persistence. The results indicated that there was no significant difference in expression of PMP-
A or PMP-B in co-infected versus C. trachomatis singly-infected cells. These data suggest that 
PMP expression is not a good indicator of chlamydial persistence when induced by HSV. 
 
INTRODUCTION 
Chlamydia trachomatis is the most common bacterial agent for sexually transmitted 
disease worldwide, causing approximately 2.86 million new infections annually in the United 
States alone (CDC, 2014). This number is likely an underestimate since chlamydia is largely a 
“silent”, or asymptomatic, infection. Chlamydia can manifest itself in inflammatory conditions 
such as urethritis or cervicitis. However, its tendency to display no visible symptoms often leads 
to untreated infections which can cause complications such as pelvic inflammatory disease, 
ectopic pregnancy, and infertility (Engleberg et al., 2013). Although chlamydia is primarily 
transmitted through sexual contact, it can be spread from an infected pregnant woman to her 
child during childbirth, since the newborn can come into contact with the pathogen upon delivery 
(CDC, 2014).  Infants infected with chlamydia can develop conjunctivitis or pneumonia, and 
chlamydia can also cause some adults to develop a rare complication known as reactive arthritis 
(Miller, 2006). As the causative agent of trachoma, the most common form of preventable visual 
impairment worldwide, C. trachomatis can also be spread through direct contact with poor 
hygiene conditions or flies (Mishori et al., 2012). Chronic chlamydial infections can lead to the 
buildup of dead epithelial cells from the continued inflammatory and healing responses of the 
host. This accumulation of necrotic cells can result in irreversible scarring in locations such as 
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the female genital tract or the eyelid, contributing to infertility and trachoma, respectively 
(Engleberg et al., 2013). 
The genus Chlamydia contains nine species, all of which are obligate intracellular 
pathogens. Chlamydial organisms must be inside living host cells to replicate. Chlamydiae can 
infect a variety of hosts, ranging from humans to amoebae (Schoborg, 2011). C. trachomatis, the 
human strain of chlamydial pathogens, targets epithelial cells and can be found in the mucosal 
membranes of the genital tract, urinary tract, eyes, or lungs (Mishori et al., 2012). C. trachomatis 
is sensitive to macrolides, tetracyclines, and fluoroquinolones; common antibiotics used to treat 
the pathogen include erythromycin, doxycycline, and azithromycin (Engleberg et al., 2013).  All 
chlamydia share a unique biphasic developmental cycle within host cells (Figure 1). After the 
epithelial host cell ingests the infectious but non-replicative elementary bodies (EB) of the 
pathogen, the vacuoles containing EB within the cell fuse to form a chlamydial inclusion. Within 
the inclusion, the EB differentiate into non-infectious but replicative reticulate bodies (RB). The 
RB use host cell metabolites for growth and replicate through binary fission. After several 
replication cycles, the RB transform back into infectious EB, which are then released by host cell 
lysis or inclusion extrusion to infect more cells (Schoborg, 2011). 
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Figure 1. The chlamydial developmental cycle. Infectious elementary bodies (EB) attach to 
and are endocytosed by host epithelial cells to form a chlamydial inclusion. The EB within the 
inclusion transform into reticulate bodies (RB), the noninfectious but replicating form of the 
bacteria. After several rounds of replication, the RB transform back into EB that are then 
released by host cell lysis to infect other cells. If stressors such as IFN- or β-lactam antibiotics 
are introduced to chlamydia-infected cells, the chlamydia will enter a state known as persistence, 
in which the bacteria are noninfectious but still viable. Persistence is characterized by the 
enlargement of RB into aberrant bodies (AB) which no longer have the ability to replicate and 
transform into infectious EB. Removal of such stressors allows the re-entry of the bacteria into 
the normal infectious cycle (Schoborg, 2011). 
 
 When chlamydia-infected host cells are exposed to a stress such as nutrient deprivation or 
certain antibiotics, the chlamydia bacteria enter a state known as persistence. Persistence is 
characterized by the enlargement of RB in the inclusion and also the inhibition of their 
replication and differentiation into EB (Hogan et al., 2004). In persistence, the bacteria are non-
infectious but still viable. It has been shown that persistent chlamydia can re-enter the normal 
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developmental cycle when stressors such as IFN-  or β-lactam antibiotics are removed from 
infected cells (Beatty et al., 1995; Kintner et al., 2014). Because chlamydia commonly cause 
recurrent infection, some researchers have suspected a link between recurrence and persistence. 
Substantial data exists from in vitro studies into this link. Experiments conducted by Dean and 
Powers (2001) have shown that persistent chlamydia can alter host cell processes by resisting 
apoptosis, or programmed cell death. Persistent forms of chlamydia have also been linked to pro-
inflammatory responses and serving as reservoirs for new infections, both of which contribute to 
chronic disease (Reveneau et al., 2005). Evidence also exists of a possible connection between 
persistence and the development of chlamydial resistance to antibiotic treatments such as 
azithromycin in cell culture (Dean, 2009).  
 Fewer in vivo studies into chlamydial persistence exist due to the difficulties of obtaining 
live and controllable organismal models. Studies conducted by Nanagara et al. (1995) are one of 
few which support the contribution of persistent chlamydia to disease chronicity in vivo, since 
tissue samples from patients with chlamydia-associated arthritis were found to contain 
characteristically persistent chlamydia. Recent developments by the Department of Biomedical 
Sciences at the Quillen College of Medicine have led to the successful development of the first 
tractable, or easily controllable, animal model of chlamydial persistence. The breakthrough 
murine model has facilitated the in vivo discovery of persistent chlamydia in infected host mice 
stressed by amoxicillin, the most commonly prescribed antibiotic for bacterial infections in the 
United States and also the treatment of choice for pregnant women infected with chlamydia 
(Campbell et al., 2012). Recent studies with this animal model have also found that persistent 
chlamydiae in vivo are more resistant to azithromycin, supporting the similar results obtained in 
vitro (Phillips-Campbell et al., 2014; Dean, 2009). 
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 Along with the biphasic developmental cycle, all chlamydial species share a unique 
family of genes encoding for polymorphic membrane proteins (PMPs). C. trachomatis expresses 
nine PMPs on the surface of its elementary bodies, designated PMP-A to PMP-I (Taylor, 2011). 
Although the role of PMPs in chlamydial pathogenesis is not fully understood, studies suggest 
that the proteins do play some role in virulence. Structural protein analysis reveals that each PMP 
subtype of C. trachomatis contains several GGAI amino acid motifs, which are associated with 
the adhesion of other organisms to host cells, and patients infected with C. trachomatis are 
known to produce antibodies for all PMPs (Gomes et al., 2006). Variance in PMP antibody 
profiles among patients infected with C. trachomatis suggests that the proteins are part of a 
mechanism of antigenic variation for the bacteria to evade the immune system, adjusting to 
different immunological pressures within infected hosts (Carrasco et al., 2011). In a study 
conducted among women with pelvic inflammatory disease, Taylor et al. (2011) found that those 
who expressed antibodies for PMP-A were less likely to achieve pregnancy or a live birth and 
those who expressed antibodies for PMP-I were more likely to have upper genital tract 
infections. Data from this study also revealed an increase of inflammatory markers in women 
with PMP-A antibodies, suggesting that PMP-A could serve as a potential biomarker for the 
increased risk of secondary sequelae from C. trachomatis infection (Taylor et al., 2011).  
 The expression of PMPs in relation to persistence has also been explored. A study by 
Carrasco et al. (2011) discovered that the transcription of some PMPs, such as PMP-B, is 
downregulated in C. trachomatis-infected cells under conditions of penicillin-induced 
persistence. Since in vitro studies by Deka et al. (2006) have found that chlamydial persistence 
can also be induced by co-infection of host cells with herpes simplex virus type-2 (HSV-2), we 
hypothesized that expression of certain PMPs, in this case PMP-A and PMP-B, would be 
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decreased under conditions of HSV-induced persistence. The question was explored to further 
determine whether PMPs could be used as biomarkers of chlamydial persistence in vivo. 
 In addition to being one of the most common sexually transmitted infections in the world, 
chlamydia is a common co-infection in human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) patients. A systematic review of 37 clinical and 
epidemiological studies of STI co-infections in HIV/AIDs patients across the world reports that 1 
in 20 people living with HIV/AIDS also have chlamydia (Kalichman et al., 2011). One widely 
used class of anti-HIV drugs is comprised of integrase strand transfer inhibitors (INSTIs). 
INSTIs target the viral enzyme integrase, which is responsible for incorporating the retroviral 
DNA of HIV into the host genome. Some integrase inhibitors in clinical use today are 
raltegravir, dolutegravir, and elvitegravir (EVG), the drug of interest to our studies (Quashie, 
2012). EVG, approved for use by the U.S. Food and Drug Administration in 2012, is a 
component of the pharmaceutical drug 
Stribild. Its mechanism of action 
consists of inhibiting integrase by 
preventing HIV-1 DNA strand transfer 
and integration (Lee et al., 2012). 
Studies have shown that EVG has 
broad antiretroviral activity, effectively 
inhibiting HIV replication, as well as 
that of simian immunodeficiency virus 
and murine leukemia virus (Shimura et al., 2008). Most INSTIs achieve their selectivity through 
the inclusion of a diketo acid moiety (DKA) in their structure, but EVG’s structure (Figure 2) 
 
Figure 2. The structure of Elvitegravir (Shimura, 2008). 
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actually contains a monoketo acid, a modified DKA, which maintains a high specificity for the 
strand transfer reaction (Quashie, 2012). 
EVG is also a quinolone derivative. Although chlamydial infections can often be 
effectively treated by fluoroquinolones such as ofloxacin and levofloxacin, research shows that 
quinolones may also have a role in persistence. Subinhibitory or low dose concentrations of 
fluoroquinolones can produce fluoroquinolone-resistant mutants of C. trachomatis (Dessus-
Babus et al., 1998). Testing conducted by Somani et al. (2000) on clinical isolates of C. 
trachomatis-infected patients who experienced treatment failure found that the chlamydiae 
exhibited multidrug resistance to common treatments such as ofloxacin. From the genotyping of 
the primary isolates and separate isolates obtained from infection relapses in those patients, it 
was found that recurrent disease was caused by the same resistant organisms and that many 
aberrant inclusions were present among the resistant strains. One theory of the researchers 
suggested that resistance may be linked to an alteration in the chlamydial life cycle resulting in 
some intermediate stage (i.e. persistence) which would make the bacteria more refractive to 
antimicrobial agents. Although other theories were also put forth as an explanation for the 
mechanism of resistance, it is possible that exposure to certain concentrations of antimicrobial 
agents such as ofloxacin induced the chlamydia to enter persistence (Somani et al., 2000). In 
another study by Patton et al. (1993), C. trachomatis-infected monkey models were treated with 
a quinolone analog therapy. Although chlamydial organisms were no longer recoverable in cell 
culture after completion of the therapy, chlamydial DNA was consistently present post-therapy, 
suggesting the presence of either dead organisms or viable organisms in an unculturable state 
(i.e. persistent organisms) (Patton et al., 1993). Since exposure to low-dose quinolones is 
implicated in chlamydial persistence and EVG is a quinolone derivative, we hypothesized that 
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EVG would inhibit chlamydial development. The question is relevant, considering the 
prevalence of chlamydial co-infections in HIV/AIDS patients and the fact that these patients 
must be on anti-HIV drugs for life. If EVG inhibits chlamydial replication, HIV patients on EVG 
would be expected to be more resistant to chlamydial infection.   
 
MATERIALS AND METHODS 
Chlamydia, HSV-2 and host cells: 
HeLa cells, a human cervical adenocarcinoma epithelial cell line (ATCC CCL2) were 
used for both studies. A human urogenital isolate of C. trachomatis E/UW-5/CX was originally 
obtained from S.P. Wang and C. Kuo (University of Washington, Seattle, WA). C. muridarum 
Weiss strain was obtained from Dr. Kyle Ramsey. The same standardized inoculum of C. 
trachomatis serovar E or C. muridarum elementary bodies, propagated in Hec1B cells (human 
endometrial cell line ATCC#HTTB-113), was used for all experiments (Wyrick et al., 1996). 
HSV-2 strain 333 stocks were obtained from Mary K. Howett. Viral stocks were prepared in 
monolayers of Vero cells (African green monkey kidney cells ATCC No. CCL-81) using 
standard techniques (Duff and Rapp, 1971).    
EVG studies:  
 
Cell culture. HeLa cells were plated and infected with C. trachomatis serovar E or C. 
muridarum Weiss and exposed to either Elvitegravir (Selleckchem.com #S2001), amoxicillin, or 
tetracycline at physiologically relevant concentrations: 
Drug Class Serum (1X) concentration Diluent 
Amoxicillin (AMX) Penicillin 11 g/mL Water (ddH2O) 
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Tetracycline (TET) Tetracycline  4.3 g/mL Water (ddH2O) 
Elvitegravir (EVG) Quinolone  1.7 g/mL Dimethyl sulfoxide  
(DMSO) 
Table 1. Physiologically relevant drug concentrations.   
Replicate cultures were either exposed to medium + diluent (DMSO or water, as appropriate), 
medium + amoxicillin, medium + tetracycline, or medium + EVG (1X [1.7 g/mL] 
concentration) and incubated at 35°C. At 48 hours post infection, samples were collected for titer 
assay, immunofluorescence staining, and transmission electron microscopy.  
 Determining EVG concentration. The physiologically relevant concentration of EVG 
was set at 1.7 g/mL (Ramanathan, 2008; “Stribild,” 2013). That is the maximum concentration 
of EVG that can be found in human serum when ingested in the form of the trademark drug 
Stribild. 
 Immunofluorescence assay (IFA) and percent infectivity. At 48 hours post infection, 
cell monolayers were fixed and permeabilized with 1 mL cold methanol for 20 minutes. Glass 
coverslips for C. trachomatis and C. muridarum were stained with anti-chlamydial MOMP stain 
and LPS stain (Bio-Rad #30702 and #30701), respectively. All coverslips were counterstained 
with DAPI and mounted on glass slides. The number of inclusions and host cell nuclei in 10 
fields/coverslip was determined at 630x magnification under oil immersion using an Axiovert 
S100 (Zeiss) microscope and Axiovert imaging software. Percent infectivity was calculated as 
the number of inclusions divided by the number of host cell nuclei per field on the coverslips. 
The data were analyzed statistically using a two-tailed t test with p<0.05 considered significant.    
 Infectious titer assay. Chlamydial titrations were conducted as previously described 
(Deka et al., 2006) using LPS and MOMP stains (Bio-Rad) to identify chlamydial inclusions 
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formed from subpassaged EB. The number of inclusion-forming units (IFU) in the undiluted 
inoculum was derived from triplicate counts and expressed as IFU/mL (Hall et al., 2014).   
 Transmission electron microscopy (TEM) processing. Cultured cells were scraped into 
gluteraldehyde/paraformaldehyde TEM fixative and incubated at 4°C for 1 hour before further 
processing. All samples were washed with cacodylate buffer and then incubated with 1% 
osmium tetroxide in cacodylate buffer for 1 hour at room temperature. Samples were washed 
again with cacodylate buffer and dehydrated with gradually increasing concentrations of ethanol 
before infiltration with Eponate 812 (Polysciences, Inc., Warrington, PA). Samples were finally 
embedded in fresh Epon, thin sectioned, and visualized using a Tecnai Philips transmission 
electron microscope at 80kV. All electron micrographs were taken at 12700x magnification.  
 
PMP studies:  
Cell culture. HeLa cells were divided into four groups for mock infection, chlamydial 
infection, HSV-2 infection, and C. trachomatis/HSV-2 double infection. Host cells were 
incubated with a dilution of crude EB stock calculated to infect greater than 80% of the cells. 
After one hour of adsorption, monolayers were refed with Minimal Essential Medium (MEM; 
Invitrogen #11095-098) and incubated at 35°C for 24 hours. Cultures were then infected with 
HSV-2 at a multiplicity of infection (MOI) of 10 plaque forming units (PFU) per cell. Mock-
infected HeLa cells were treated similarly, except they were exposed to either 2SPG (0.2M 
sucrose, 6mM NaH2PO4, 15mM Na2HPO4, 5mM L-glutamine, pH 7.2; mock C. trachomatis 
infection) or growth medium (mock viral infection). After HSV adsorption, monolayers were 
refed with MEM and incubated at 35°C for 20 hours.   
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Flourescent staining and microscopy. The same staining procedures were used for 
PMP-A and PMP-B. Fluorescence analysis samples were prepared as described previously using 
formaldehyde fixation (Deka et al., 2006). Fixed cells were stained using the Carrasco et al. 
(2011) protocol. Anti-PMP primary antibodies were a kind gift from Dr. Patrick Bavoil (Tan, 
2009).  
To make a 1:25 initial dilution of anti-PMP primary antibody (guinea pig), 4 µL of anti-
PMP primary antibody was added into a tube containing 96 µL of PBS (phosphate buffered 
saline) washing buffer. Fixed HeLa cells were washed 3 times in 1X PBS washing buffer, and 
then 100 µl of diluted primary antibody was added into each well of HeLa cells. The plate was 
then placed on a gyrator shaker at a speed of 3.5 for 30 minutes at room temperature to pre-
adsorb the antisera. This process removes antibodies that cross-react to HeLa cell antigens (to 
reduce staining background), while anti-chlamydia PMP antibodies remain. The resulting pre-
absorbed antibody was then used as the primary antibody for all subsequent fluorescence 
staining of chlamydia-infected cells. The secondary antibody (Alexa Fluor 488 goat anti-guinea 
pig (IgG)) (Invitrogen #A-11073) was diluted to a concentration of 1:500 with PBS washing 
buffer and DAPI solution. 
For fluorescence staining, 10 L drops of dilute primary antibody were pipetted onto 
parafilm. Sample coverslips were washed with PBS washing solution and inverted onto the 
primary antibody drops, cell monolayer down. Coverslips were incubated at 37°C for 1 hour and 
then washed with PBS washing buffer before secondary staining. Ten L drops of secondary 
antibody were pipetted onto parafilm, and coverslips were inverted onto the drops and incubated 
at 37°C for 30 minutes. Coverslips were then washed with PBS washing buffer again before 
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being mounted (Fluoromount Fisher #OB100-01) on glass slides and stored in a dark drawer to 
dry.  
Using an Axiovert S100 (Zeiss) microscope and Axiovert imaging software, the intensity 
of 50 inclusions from singly-infected cells and 50 chlamydial inclusions from co-infected cells 
were quantified and compared for each one of three replicates. Inclusion intensity measurements 
were divided by inclusion area measurements, and the resulting measurements for all three 
replicates of each sample were averaged to compare the expression of the PMP of interest in the 
chlamydial-infected cells versus the chlamydial/HSV-2 co-infected cells. Statistical analyses of 
the data were conducted using a two-tailed t test with p<0.05 considered significant.    
 
RESULTS 
EVG studies:  
 
 Several EVG studies were conducted. The following are representative data for the 
effects of EVG found on both the development of C. trachomatis and C. muridarum. The results 
encapsulate the percent infectivity obtained from IFA staining, production of infectious progeny 
from chlamydial titer assay, and chlamydial inclusion morphology from TEM analysis. Percent 
infectivity is equal to the number of chlamydial inclusions divided by the number of host cells 
counted per microscopic field on sample coverslips. Inclusion and cell counts were conducted on 
individual IFA images (Figures 4 and 6, for example) and average percent infectivity values 
were then calculated (Figures 3 and 5). Percent infectivity was used to determine if any great 
differences in infectivity, which could have affected experimental results, existed among the 
samples. 
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Figure 4. IFA-stained cells at magnification 630x under oil immersion: A. mock B. CtE 
+amoxicillin (AMX) C. CtE +DMSO D. CtE +EVG 1X concentration (1.7 g/mL). Host cell 
nuclei are stained blue by DAPI stain and chlamydial inclusions are stained green by MOMP 
stain.    
Figure 3. EVG Exposure Does Not Inhibit C. trachomatis Inclusion Formation. Percent 
infectivity (number of chlamydial inclusions divided by number of host cell nuclei) for three 
replicates (n=3) of C. trachomatis serovar E-infected samples stained using 
immunofluorescence assay (IFA) staining. An asterisk (*) indicates a statistically significant 
difference found after conducting a two-tailed t test using p<0.05 for significance. Mock, 
AMX, and TET samples were compared to CtE –DMSO positive control samples (data not 
shown). EVG samples were compared to the CtE +DMSO positive control samples. These 
data were obtained from study EVG.02. 
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Figure 5. EVG Exposure Does Not Inhibit C. muridarum Inclusion Formation. Percent 
infectivity (number of chlamydial inclusions divided by number of host cell nuclei) for three 
replicates (n=3) of C. muridarum-infected samples stained using immunofluorescence assay 
(IFA) staining. An asterisk (*) indicates a statistically significant difference found after 
conducting a two-tailed t test using p<0.05 for significance. Mock, AMX, and TET samples 
were compared to Cm –DMSO positive control samples (data not shown). EVG samples 
were compared to the Cm +DMSO positive control samples. These data were obtained from 
study EVG.07. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. IFA-stained cells at magnification 630x under oil immersion: A. Cm +tetracycline 
(TET) B. Cm +AMX C. Cm +DMSO D. Cm +EVG 1X concentration (1.7 g/mL). Host cell 
nuclei are stained blue by DAPI stain and chlamydial inclusions are stained green by LPS stain.    
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As expected, mock infected monolayers for both C. trachomatis (Figure 3) and C. 
muridarum (Figure 5) did not contain inclusions since those samples were not infected with 
chlamydia. Tetracycline-exposed C. trachomatis (Figure 3) and C. muridarum (Figure 5) did 
not display any inclusions, as was also expected, since tetracycline effectively kills chlamydia 
and prevents inclusions from developing. In contrast, amoxicillin-exposed samples for each 
species did contain inclusions. Amoxicillin served as a control for chlamydial persistence, so the 
drug did not inhibit the formation of inclusions. Diluent control cultures of chlamydia containing 
ddH2O (the diluent used for TET and AMX) were also performed (data not shown). Chlamydial 
samples exposed to DMSO were used as a comparative reference for EVG samples since the 
EVG samples contained DMSO as the diluent for the drug. Statistical analysis for EVG-exposed 
versus unexposed chlamydia for both species showed that there was not a significant decrease in 
the formation of inclusions (Figures 3 and 5). It was thus determined that EVG did not 
significantly alter the percent infectivity and therefore did not pose a significant problem for 
interpreting other experimental results obtained for either EVG-exposed C. trachomatis or C. 
muridarum.  
IFA images reveal a first look into inclusion morphology for the treated samples. Mock 
samples (Figure 4A) only exhibit blue host cell nuclei since no chlamydia are present to bind the 
FITC-labeled anti-LPS antibody (which fluoresces green). Residues of killed chlamydial 
inclusions are labeled by anti-LPS in tetracycline-exposed chlamydial cultures (Figure 6A). 
Amoxicillin-exposed chlamydia (Figures 4B, 6B) appeared persistent. Large, aberrant bodies 
can be seen within the insets of the inclusions. Chlamydia exposed to DMSO (Figures 4C, 6C) 
and EVG (Figures 4D, 6D) displayed very similar inclusion morphologies, which were clearly 
distinct from the amoxicillin-exposed chlamydia. 
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Figure 7. EVG Exposure Reduces Production of Infectious C. trachomatis Elementary 
Bodies. Titer assay results showing the number of infectious, recoverable EB counted from C. 
trachomatis serovar E-infected samples. An asterisk (*) indicates a statistically significant 
difference compared to the CtE +DMSO positive control samples found after conducting a two-
tailed t test using p<0.05 for significance.   
  
Figure 8. EVG Exposure Reduces Production of Infectious C. muridarum Elementary 
Bodies. Titer assay results showing the number of infectious, recoverable EB counted from C. 
muridarum-infected samples. An asterisk (*) indicates a statistically significant difference 
compared to the Cm +DMSO positive control samples found after conducting a two-tailed t test 
using p<0.05 for significance. 
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Titer results (Figures 7 and 8) for both C. trachomatis and C. muridarum showed that 
mock-, AMX-, and TET-exposed samples did not produce infectious EB, as expected. Although 
chlamydia can form inclusions when AMX exposed, the organisms are persistent (noninfectious) 
and thus not producing infectious EB. Titer data revealed a significant decrease in the production 
of viable infectious progeny from chlamydia exposed to EVG at the physiologically relevant 
(1X) concentration. Compared to the DMSO-exposed chlamydia, there was a much lower 
number of recoverable EB found from the EVG-exposed chlamydia. These results were 
consistently reproduced in several experimental replications and suggest that exposure to EVG 
causes a reduction in the production of infectious EB.   
Transmission electron micrographs (TEMs) (Figure 9 below) provided an up-close look 
into individual inclusions. As the figure shows, the morphology of C. trachomatis and C. 
muridarum inclusions appears very similar among samples exposed to DMSO and samples 
exposed to EVG. Both EB, indicated by yellow arrows, and RB, indicated by white arrows, are 
scattered throughout. This confirms the results of the IFA images, which also appeared to show 
morphologically similar inclusions between DMSO- and EVG-exposed samples. TEMs of 
characteristically persistent inclusions (images not shown) display very large, aberrant bodies. 
The aberrant bodies are few in number since persistent chlamydia cease replicating, and there is 
also an absence of the small, dark infectious EB since persistent chlamydia are also 
noninfectious. 
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Figure 9. EVG Exposure Does Not Significantly Alter C. trachomatis or C. muridarum 
Morphology. Transmission electron micrographs at magnification 12700x: A. CtE +DMSO 
B. CtE +EVG 1X concentration (1.7 g/mL) C. Cm +DMSO D. Cm + EVG 1X concentration. 
White arrows indicate RB and yellow arrows indicate EB within the chlamydial inclusions. 
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PMP studies:  
The following are results from our studies of the expression of both PMP-B and PMP-A 
under conditions of HSV-induced persistence. Chlamydial PMP expression was measured by the 
amount of inclusion intensity from fluorescence staining divided by inclusion area.  
 
 
 
 
 
 
 
 
 
 
Figure 10. Co-infection Does Not Significantly Alter C. trachomatis PMP-B Accumulation. 
Average inclusion intensity/area measurements for three replicates (n=3) of PMP-B stained 
CtE/HSV co-infected versus CtE-infected cells. There was no significant difference between 
inclusion intensity staining with PMP-B antibody between co-infected and singly-infected 
samples (p>0.05).   
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Figure 11. HeLa cells stained with PMP-B antibody at 400x magnification. A. mock B. HSV-
infected C. CtE/HSV co-infected D. CtE-infected. 
 
 
 
 
 
 
 
 
Figure 12. Co-infection Does Not Significantly Alter C. trachomatis PMP-A Accumulation. 
Average inclusion intensity/area measurements for three replicates (n=3) of PMP-A stained 
CtE/HSV co-infected versus CtE-infected cells. There was no significant difference between 
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inclusion intensity staining with PMP-A antibody between co-infected and singly-infected 
samples (p>0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. HeLa cells stained with PMP-A antibody at 400x magnification. A. mock B. HSV-
infected C. CtE/HSV co-infected D. CtE-infected. 
 
 Results (Figures 10 and 11) revealed that there is no significant difference in expression 
of either PMP-B or PMP-A staining intensity between chlamydia-infected and chlamydia/HSV-2 
co-infected cells. Representative images of PMP-B and PMP-A expression can be viewed in 
Figure 11 and Figure 13, respectively.   
 
DISCUSSION 
 Contrary to our initial hypothesis, the data from our PMP studies show that there was no 
significant difference in expression of PMP-A or PMP-B between unstressed chlamydia and 
chlamydia stressed by HSV-2. This suggests that neither PMP-B nor PMP-A play a special role 
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in chlamydial persistence when induced by HSV-2, leading to the conclusion that neither PMP 
would serve as a good biomarker of persistence when induced by HSV-2. Since Carrasco et al. 
(2011) did find some decreased levels of PMP expression among persistent chlamydia induced 
by penicillin, it seems that whether or not PMP expression changes during persistence may vary 
according to the type of stimulus that is used to induce persistence. Experimentation involving 
different inducers of persistence, such as IFN- or other β-lactams like amoxicillin, would be 
helpful in further exploring the question. 
 The results from EVG studies also lead to further questions. It can be directly observed 
from both IFA and TEM visuals that the appearance of EVG treated and untreated chlamydial 
inclusions is very similar. Exhibiting inclusions with EB and RB similar to the DMSO-exposed 
chlamydia, EVG exposure appears to not alter normal inclusion formation. It is clear by 
comparison to references of persistence such as the amoxicillin-exposed chlamydia that EVG is 
not inducing chlamydia into persistence. This would point to the conclusion that EVG has no 
effect on chlamydial development, but the results of infectious titer assays indicate otherwise. 
Since titer results revealed that EVG exposure significantly reduces the production of infectious 
EB in both C. trachomatis and C. muridarum, it appears that EVG does inhibit chlamydial 
development in vitro at physiologically relevant concentrations. Since this inhibition of the 
production of infectious progeny does not seem to be linked to persistence, it appears that 
another mechanism may be at work.  
Although the mechanism of this inhibition of chlamydial development is currently 
unknown, there are several possibilities. Although TEMs indicate that EB are still present within 
chlamydia exposed to EVG, titer assays indicate that the EB are significantly less infectious. 
EVG could be reducing the infectious nature of EB after they are produced. It is possible, for 
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example, that the drug could be interacting with and partially inactivating EB surface proteins 
that are required for the EB to infect new cells. It is also possible that EVG could be delaying the 
release of EB from inclusions or that its activity could differ depending on the timing of the 
drug’s addition to chlamydia infected cells. Further experimentation involving variations in 
timing of the drug’s addition to infectious samples could shed more light on its activity.  
Preliminary studies involving mice have been conducted in order to ascertain the effects 
of EVG in vivo. A group of 4 mice were administered with Stribild, the pharmaceutical drug 
form of EVG, to observe effects on chlamydial shedding. Compared to untreated mice, the mice 
administered with Stribild exhibited a shorter duration of chlamydial shedding by about 6 days. 
Stribild treated mice also seemed to show less gross pathology as well. Although an interesting 
finding, these results are interpreted with caution due to the very preliminary nature of the study. 
Only a small number of mice were used, so the reliability of the data is questionable until the 
experiment can be reproduced on a greater scale.   
 Although not serving as a persistence-inducer, EVG clearly has some inhibitory effect on 
the development of chlamydia in vitro. Further experiments involving animal models or other 
anti-HIV drugs similar to EVG may be used in the future to understand more about the 
mechanism at work.  
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